CN108785414A - Improve composition and its application of osteoarthritic inflammation - Google Patents
Improve composition and its application of osteoarthritic inflammation Download PDFInfo
- Publication number
- CN108785414A CN108785414A CN201810937626.3A CN201810937626A CN108785414A CN 108785414 A CN108785414 A CN 108785414A CN 201810937626 A CN201810937626 A CN 201810937626A CN 108785414 A CN108785414 A CN 108785414A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- composition
- osteoarthritic inflammation
- osteoarthritic
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Abstract
The invention discloses a kind of composition improving osteoarthritic inflammation and its applications, improve the composition of osteoarthritic inflammation, including following weight percentage components：Rice bran alcohol 30~60%, Euglena 25-50%, green ground coffee 7-10%, yeast peptide 7-10%.The present invention is in view of the shortcomings of the prior art, a kind of composition improving osteoarthritic inflammation of offer and its application.The composition is rice bran alcohol, Euglena, green ground coffee, yeast peptide, and monomer component has no obvious effect to arthritis, can improve arthritis after compounded combination, and these components are naturally without side-effects to human body, non-stimulated, is safely and effectively product.There is this composition reducing blood lipid, anti-aging to alleviate vegetalitas sleep disturbance, and splendid uvioresistant and oxidation resistance also have weight-reducing, anti-flu and raising immunity function.
Description
Technical field
The present invention relates to the composition containing rice bran alcohol and its answer.
Background technology
Currently, the arthritic drug of western medical treatment is more, it is most of since doctor trained in Western medicine is not yet completely understood the mechanism of the disease
Based on anti-inflammatory analgesic, radical cure effect cannot be played, and the long-term use of these medicines is very big to the side effect of human body, be easy after treatment
Recurrence, inestimable body and menticide are brought to patient；Though the therapy of traditional Chinese medicine can make stiff articular muscle
Loosened, dredging the channel, swelling and pain relieving, but Chinese medicine preparation compatibility is complicated, eats inconvenience, and the toxic secondary, thorn of some Chinese medicines
Swash effect；Although physical therapy and acupuncture and moxibustion therapy adverse reaction are smaller, its late result still seldom arrives affirmative.
Invention content
The object of the present invention is to provide a kind of composition improving osteoarthritic inflammation and its applications, to overcome the prior art to deposit
Defect.
The composition of the improvement osteoarthritic inflammation, including following weight percentage components：
Animal experiment and clinical research prove that the composition of the improvement osteoarthritic inflammation has obviously arthritis
Therapeutic effect can be used for prepare treatment of arthritis drug, the arthritis includes arthralgia, articular pain, joint
Swelling and joint motion；
Dosage is generally 150~450mg/ days；
Commercially produced product can be used in the rice bran alcohol, Euglena, as Huzhou Sifeng Biochem Co., Ltd. provides
Rice bran alcohol, the new raw-food material Euglena that Tong Yuan companies provide；
The drug of the present invention for improving osteoarthritic inflammation, can be applied to needs by the form of pharmaceutical composition and control
The drug and medicine and pharmacology of the improvement osteoarthritic inflammation of the patient for the treatment of, the pharmaceutical composition, including therapeutically effective amount
Upper acceptable carrier, the carrier is for example：Disintegrant such as croscarmellose sodium；Adhesive such as cellulose derives
Object, gelatin, polyvinylpyrrolidone etc.；Filler such as starch, lactose, microcrystalline cellulose etc.；Lubricant such as magnesium stearate etc.；Separately
Outside, other adjuvants such as flavouring agent and sweetener can also be added in the composition.
The pharmaceutical composition of the present invention can be prepared into conventional solid pharmaceutical preparation, such as tablet, capsule, oral preparation：Such as
Pulvis etc.；The dosage forms such as injection can also be prepared into for injecting.
Preferably, in the pharmaceutical composition, the weight content of the drug of the described improvement osteoarthritic inflammation is 40~
70%；
Preferably, the pharmaceutical composition, including following weight percentage components：
The disintegrant is selected from microcrystalline cellulose, croscarmellose sodium, povidone or sodium carboxymethyl starch；
The filler is selected from microcrystalline cellulose, lactose, maltodextrin, starch or sugar alcohol/Icing Sugar etc.；
The adhesive be selected from hydroxypropyl methyl cellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, xanthans or
Sodium carboxymethylcellulose pyce etc.；
The lubricant is selected from magnesium stearate, silica, talcum powder or polyethylene glycol etc.；
The preparation method of the pharmaceutical composition is conventional, each component is mixed, using side well known in the art
Method tabletting or filling are paid.
The beneficial effects of the invention are as follows：
The present invention is in view of the shortcomings of the prior art, a kind of composition improving osteoarthritic inflammation of offer and its application.The combination
Object is rice bran alcohol, Euglena, green ground coffee, yeast peptide, and monomer component has no obvious effect to arthritis, can change after compounded combination
Kind arthritis and these components are naturally without side-effects to human body, it is non-stimulated, it is safely and effectively product.This composition has drop blood
Fat, anti-aging alleviate vegetalitas sleep disturbance, and splendid uvioresistant and oxidation resistance also have weight-reducing, anti-flu and carry
High immunity function.
Specific implementation mode
Embodiment 1
Formula：(weight)
Each component is mixed, tabletting with method known in this field is then adopted, you can obtains the pharmaceutical composition.
Number is alimentation composition 1.
Embodiment 2
Formula：(weight)
Each component is mixed, tabletting with method known in this field is then adopted, you can obtains the pharmaceutical composition.
Number is alimentation composition 2.
Embodiment 3
1. zoopery
(1) animal selects：Just ablactation Wistar rats 40 are selected, between weight 80-100g.The raising of rat single cage is random
It is divided into 4 groups, every group 10.Animal is placed in different cages, and adapts to before the experiments at least one week.Animal Lab. is equipped with certainly
Dynamic temperature (22 ± 1 DEG C) and Lighting control (12 hours illumination/12 hour dark).The experimental procedure of animal and animal feeding in accordance with
National Institutes of Health《Management of laboratory animal and service manual》System criterion carry out.
(2) drug administration：It is all made of oral medication, dosage is expressed as dosage (g)/weight (kg)
(3) acute inflammation model：The anti-inflammatory effect of this composition is studied using the acute inflammation model for intersecting the induction of dish glue.
Rat receives plantar rising pouring in left back foot and penetrates carrageenan (0.1ml, 1%, 0.85% saline；Sigma
Chemical Co., St Louis, MO, USA).
Animal fasting 24 hours before the experiments respectively will be right before injection intersects dish glue 1 hour and after 24 hours
According to group, antibiotic group and alimentation composition 1,2 feeding animals of alimentation composition, dosage and 1 the results are shown in Table
(4) assessment of foot swelling experiment
Each animal foot is measured using sufficient device for volume measurement (Plethysmometer 7150, Ugo Basile, Italy)
Swelling volume (presses ml), accuracy to 2 significant digits.2 before and after carrageenin injection, carry out within 4,6,24 hours
It measures.The swelling rate of pawl is sufficient percent by volume difference and is calculated by following formula：Swelling rate (%)=(A-B) * 100/B, this
In A indicate injection after different time points sufficient volume, B indicate injection before sufficient volume.
As a result it is expressed as average value ± SD.Data analysis uses variance analysis (ANOVA), compares two-by-two using LSD methods, p<
0.05 is with significant.
(5) detection of Serum Indexes and erythrocyte sedimentation rate
(6) experimental result
The effect of 1 antibiotic of table and alimentation composition to the rat paw edema caused by intersection dish glue
Note：* *, p<0.001；*, p<0.01；*, p<0.05, compared with control group is at same time point
Table 2 Serum Indexes and erythrocyte sedimentation rate are influenced (mm/h,)
*：P < 0.05 compared with the control group,
Compared with the control group, there were significant differences to TNF, T-SOD, BSR for alimentation composition, without significance difference compared with antibiotic
Different i.e. alimentation composition is suitable with antibiotic group effect.
Known by table 1, table 2, antibiotic group acts on obviously erythrocyte sedimentation rate with alimentation composition 2, has clear improvement to Serum Indexes.
2. clinical research
(1) clinical subjects：Test group 75, wherein male 30, women 45, oldest 78 years old, minimum 51
In year, 60.82 years old average, course of disease longest 20 years is most 1 year short, 4.03 years average.Control group 1：75, wherein male 35, women
40, the oldest 78 years old, 50 years old minimum, 59.59 years old average, course of disease longest 18 years is most 6 months short, 3.35 years average.Control
Group 2：75, wherein male:33, women 42, oldest 76 years old, minimum 52 years old, 60.02 years old average, the course of disease was most
It is 18.5 long, it is most 8 months short, it is 3.83 average.It is statistically analyzed P>0.05, illustrate the two in terms of gender, age, the course of disease
Without significant difference, it is comparable.
(2) therapy：1 diclofenac sodium enteric-coated tablets of control group；Control group 2 takes orally Euglena powder piece, dosage：300mg/
It；Test group takes orally the present composition (embodiment 2)；Dosage：One time a day, 2 tablets once；28 days periods
(3) observation of curative effect：
Clinical symptoms：Arthralgia, articular pain, arthroncus, joint motion；
(4) experimental result
Clinicing symptom observation
Compared with control group 1, for test group without significant difference, two groups of effects are suitable；Compared with control group 2, test group effect
Significantly, illustrate that the effect of new compositions is substantially better than single Euglena powder piece；In subsequent long-term efficacy investigation, test group patient
Substantially it does not recur.
Claims (8)
1. improving the composition of osteoarthritic inflammation, which is characterized in that including following weight percentage components：
2. pharmaceutical composition includes the drug and medicine and pharmacology of the improvement osteoarthritic inflammation described in claim 1 of therapeutically effective amount
Upper acceptable carrier.
3. pharmaceutical composition according to claim 2, which is characterized in that the weight of the drug of the improvement osteoarthritic inflammation
It is 40~70% to measure content.
4. pharmaceutical composition according to claim 2, which is characterized in that including following weight percentage components：
5. pharmaceutical composition according to claim 4, which is characterized in that the disintegrant is selected from microcrystalline cellulose, hands over
Join sodium carboxymethylcellulose, povidone or sodium carboxymethyl starch；
The filler is selected from microcrystalline cellulose, lactose, maltodextrin, starch or sugar alcohol/Icing Sugar；
The adhesive is selected from hydroxypropyl methyl cellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, xanthans or methyl
Sodium cellulosate；
The lubricant is selected from magnesium stearate, silica, talcum powder or polyethylene glycol.
6. the composition according to claim 1 for improving osteoarthritic inflammation, which is characterized in that the arthritis includes closing
Save pain, articular pain, arthroncus and joint motion.
7. according to claim 2~5 any one of them pharmaceutical composition, which is characterized in that the arthritis includes joint
Pain, articular pain, arthroncus and joint motion.
8. according to claim 2~5 any one of them pharmaceutical composition, which is characterized in that the pharmaceutical composition is solid
Body preparation, oral preparation or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810937626.3A CN108785414A (en) | 2018-08-17 | 2018-08-17 | Improve composition and its application of osteoarthritic inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810937626.3A CN108785414A (en) | 2018-08-17 | 2018-08-17 | Improve composition and its application of osteoarthritic inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108785414A true CN108785414A (en) | 2018-11-13 |
Family
ID=64080220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810937626.3A Pending CN108785414A (en) | 2018-08-17 | 2018-08-17 | Improve composition and its application of osteoarthritic inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108785414A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740112A (en) * | 2013-12-26 | 2015-07-01 | 上海宣泰生物科技有限公司 | Application of composition of lycopene and grape seed in preparation of drug used for treating arthritis |
| CN106937987A (en) * | 2016-01-04 | 2017-07-11 | 上海宣泰生物科技有限公司 | Self-emulsifying eicosapentaenoic acid nutrient composition and its application |
-
2018
- 2018-08-17 CN CN201810937626.3A patent/CN108785414A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740112A (en) * | 2013-12-26 | 2015-07-01 | 上海宣泰生物科技有限公司 | Application of composition of lycopene and grape seed in preparation of drug used for treating arthritis |
| CN106937987A (en) * | 2016-01-04 | 2017-07-11 | 上海宣泰生物科技有限公司 | Self-emulsifying eicosapentaenoic acid nutrient composition and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105753935A (en) | Small-molecule peptides of sunflower head as well as preparation method and medical application of small-molecule peptide | |
| JP3806427B2 (en) | New painkiller | |
| CN101366844B (en) | New use of loquat flower and its extract | |
| CN100382815C (en) | Compound composition for treating arthralgia caused by wind-dampness and preparation thereof | |
| CN104740112A (en) | Application of composition of lycopene and grape seed in preparation of drug used for treating arthritis | |
| CN105343056A (en) | Oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application | |
| CN1709302A (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN107669991A (en) | A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof | |
| CN109453169B (en) | Application of bulleyaconitine A | |
| CN108785414A (en) | Improve composition and its application of osteoarthritic inflammation | |
| WO2016169487A1 (en) | Use of forsythin, forsythin derivatives and composition of forsythin and forsythiaside in the preparation of anti-inflammatory drugs | |
| CN113750205A (en) | Traditional Chinese medicine composition for relieving and/or treating female reproductive system diseases | |
| WO2016127771A1 (en) | Application of 20(r)-ginsenoside rg3 in preparing drug or healthcare product for alleviating or/and treating rheumatoid disease and drug containing 20(r)-ginsenoside rg3 | |
| CN103585545B (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN103356630A (en) | Medicinal composition containing pentoxifylline and prucalopride and medical application thereof | |
| CN102579947B (en) | Chinese medicinal composition and preparation method thereof | |
| CN106937987A (en) | Self-emulsifying eicosapentaenoic acid nutrient composition and its application | |
| CN115252713B (en) | Traditional Chinese medicine composition for treating obesity and application thereof | |
| TWI720511B (en) | Use of composition containing labisia pumila var. alata extracts in alleviating depression related symptoms | |
| CN114392331A (en) | Preparation containing Agkistrodon for treating gouty arthritis | |
| CN101693058B (en) | Medicament for preventing and treating cold and inflammation infection | |
| CN101940585A (en) | Composite using orientin-2'-O-beta-L-galactoside as main component and application thereof | |
| Jadhav et al. | Formulation And In-vitro Evaluation Of Pulsatile Release Of Diltiazem Hydrochloride | |
| CN102085331A (en) | Drug for treating gout | |
| WO2023284426A1 (en) | Anti-gout celery seed-flos sophorae immaturus extract and febuxostat pharmaceutical composition, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181113 |